MSB 2.17% $1.13 mesoblast limited

Ann: Change in substantial holding, page-65

  1. 641 Posts.
    lightbulb Created with Sketch. 96
    Mesoblast likely to raise cash after FDA setbackThe stem cell-focused biotech has been rebuffed again by the US Food and Drug Administration, hitting its shareholder hard, including billionaire Melbourne investor Alex Waislitz.



    Source: https://www.theaustralian.com.au/subscribe/news/1/?sourceCode=TAWEB_WRE170_a_GGL&dest=https%3A%2F%2Fwww.theaustralian.com.au%2Fbusiness%2Fcompanies%2Fmesoblast-raises-an-extra-605m-still-has-alex-waislitzs-support-who-concedes-its-been-a-long-journey%2Fnews-story%2Fc8be3e464d46c6016dcca96b261b68ee&memtype=anonymous&mode=premium&v21=dynamic-high-test-score&V21spcbehaviour=appendend
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
(20min delay)
Last
$1.13
Change
-0.025(2.17%)
Mkt cap ! $1.284B
Open High Low Value Volume
$1.15 $1.16 $1.11 $7.363M 6.488M

Buyers (Bids)

No. Vol. Price($)
5 94863 $1.13
 

Sellers (Offers)

Price($) Vol. No.
$1.13 5000 2
View Market Depth
Last trade - 16.10pm 26/07/2024 (20 minute delay) ?
MSB (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.